Suppr超能文献

CBX3 通过调节细胞周期进程促进 HCC 的发展,受 miR-139 调控。

CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression.

机构信息

Department of Infectious Diseases, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.

Department of Hepatobiliary Surgery, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang, Henan, China.

出版信息

Cell Cycle. 2022 Aug;21(16):1740-1752. doi: 10.1080/15384101.2022.2068329. Epub 2022 Apr 26.

Abstract

Hepatocellular carcinoma (HCC), a major primary liver cancer, is one of the most lethal malignancies worldwide. Increasing evidence has demonstrated that chromobox protein homolog 3 (CBX3) functions as an oncogene in different cancers. However, its expression profiles and biological functions in HCC remain unknown. Data on CBX3 expression in HCC acquired from the GEO and TCGA databases were analyzed. The biological functions of CBX3 in HCC were examined by in vitro experiments. Bioinformatics analysis, qRT-PCR and western blotting were performed to explore the mechanism of CBX3 in HCC. CBX3 mRNA was upregulated in HCC tissues, and overexpression of CBX3 mRNA was negatively correlated with malignancies and poor prognosis in HCC patients. CBX3 knockdown decreased growth, migration and invasion of HCC cells in vitro. Moreover, bioinformatics analysis and experimental observation indicated that CBX3 expression was correlated with cell cycle regulatory proteins in HCC cells. Finally, starBase predicted that miR-139 could directly target CBX3 in HCC. Confirmatory experiments verified that miR-139 overexpression attenuated HCC cell proliferation and migration, and these effects could be reversed by overexpressing CBX3. Our results showed that the miR-139/CBX3 axis may be involved in HCC development by regulating cell cycle progression and may be a promising target in the treatment of HCC.

摘要

肝细胞癌(HCC)是一种主要的原发性肝癌,是全球最致命的恶性肿瘤之一。越来越多的证据表明,染色盒蛋白同源物 3(CBX3)在不同的癌症中作为癌基因发挥作用。然而,其在 HCC 中的表达谱和生物学功能尚不清楚。本研究分析了从 GEO 和 TCGA 数据库中获得的关于 CBX3 在 HCC 中表达的数据。通过体外实验研究了 CBX3 在 HCC 中的生物学功能。通过生物信息学分析、qRT-PCR 和 Western blot 实验探索了 CBX3 在 HCC 中的作用机制。CBX3 mRNA 在 HCC 组织中上调,并且 CBX3 mRNA 的过表达与 HCC 患者的恶性程度和不良预后呈负相关。CBX3 敲低可降低 HCC 细胞的体外生长、迁移和侵袭能力。此外,生物信息学分析和实验观察表明,CBX3 在 HCC 细胞中的表达与细胞周期调控蛋白相关。最后,starBase 预测 miR-139 可以直接靶向 HCC 中的 CBX3。验证实验证实,miR-139 的过表达可减弱 HCC 细胞的增殖和迁移能力,而过表达 CBX3 可逆转这些作用。我们的研究结果表明,miR-139/CBX3 轴可能通过调节细胞周期进程参与 HCC 的发生,可能成为 HCC 治疗的有前途的靶点。

相似文献

1
CBX3 regulated by miR-139 promotes the development of HCC by regulating cell cycle progression.
Cell Cycle. 2022 Aug;21(16):1740-1752. doi: 10.1080/15384101.2022.2068329. Epub 2022 Apr 26.
3
CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
Aging (Albany NY). 2019 Aug 2;11(15):5483-5497. doi: 10.18632/aging.102132.
4
lncRNA KCNQ1OT1 reverses the effect of sevoflurane on hepatocellular carcinoma progression via regulating the miR-29a-3p/CBX3 axis.
Braz J Med Biol Res. 2021 May 17;54(7):e10213. doi: 10.1590/1414-431X2020e10213. eCollection 2021.
5
Functions as a Tumor Suppressor in Hepatocellular Carcinoma by Targeting Ribosomal Protein SA.
Biomed Res Int. 2020 Sep 5;2020:3280530. doi: 10.1155/2020/3280530. eCollection 2020.
7
Long non-coding RNA HOTAIR promotes hepatocellular carcinoma progression by regulating miR-526b-3p/DHX33 axis.
Genes Genomics. 2021 Aug;43(8):857-868. doi: 10.1007/s13258-021-01098-9. Epub 2021 Apr 12.
8
MicroRNA-1251-5p promotes tumor growth and metastasis of hepatocellular carcinoma by targeting AKAP12.
Biomed Pharmacother. 2020 Feb;122:109754. doi: 10.1016/j.biopha.2019.109754. Epub 2019 Dec 30.
9
Down-regulation of EVA1A by miR-103a-3p promotes hepatocellular carcinoma cells proliferation and migration.
Cell Mol Biol Lett. 2022 Oct 22;27(1):93. doi: 10.1186/s11658-022-00388-8.
10
MicroRNA-139-5p negatively regulates NME1 expression in hepatocellular carcinoma cells.
Adv Clin Exp Med. 2022 Jun;31(6):655-670. doi: 10.17219/acem/146579.

引用本文的文献

本文引用的文献

1
CBX3/HP1γ promotes tumor proliferation and predicts poor survival in hepatocellular carcinoma.
Aging (Albany NY). 2019 Aug 2;11(15):5483-5497. doi: 10.18632/aging.102132.
2
MicroRNA-139 inhibits hepatocellular carcinoma cell growth through down-regulating karyopherin alpha 2.
J Exp Clin Cancer Res. 2019 May 2;38(1):182. doi: 10.1186/s13046-019-1175-2.
4
CBX3 predicts an unfavorable prognosis and promotes tumorigenesis in osteosarcoma.
Mol Med Rep. 2019 May;19(5):4205-4212. doi: 10.3892/mmr.2019.10104. Epub 2019 Mar 28.
5
MiR-139-5p, miR-940 and miR-193a-5p inhibit the growth of hepatocellular carcinoma by targeting SPOCK1.
J Cell Mol Med. 2019 Apr;23(4):2475-2488. doi: 10.1111/jcmm.14121. Epub 2019 Feb 1.
6
Enolase-1 serves as a biomarker of diagnosis and prognosis in hepatocellular carcinoma patients.
Cancer Manag Res. 2018 Nov 15;10:5735-5745. doi: 10.2147/CMAR.S182183. eCollection 2018.
7
Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.
Gastroenterology. 2019 Jan;156(2):492-509. doi: 10.1053/j.gastro.2018.11.001. Epub 2018 Nov 4.
8
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
10
Low microRNA-139 expression associates with poor prognosis in patients with tumors: A meta-analysis.
Hepatobiliary Pancreat Dis Int. 2019 Aug;18(4):321-331. doi: 10.1016/j.hbpd.2018.09.016. Epub 2018 Sep 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验